Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Asthma Drugs Market Forecast: Value Set To Climb From $26.3 Billion To $33.61 Billion
The asthma drugs market has shown strong growth in recent years. It is projected to expand from $24.93 billion in 2025 to $26.3 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.5%. This historical growth can be attributed to factors such as the increasing prevalence of asthma, limited access to advanced therapies, a high incidence of respiratory infections, traditional inhaler usage, and awareness campaigns conducted by health organizations.
The asthma drugs market size is anticipated to expand significantly in the near future. It is forecast to grow to $33.62 billion in 2030, at a compound annual growth rate (CAGR) of 6.3%. The projected growth for this period stems from developments in biologics and monoclonal antibodies, the increasing adoption of smart inhalers, enhanced digital health integration, the expansion of preventive care programs, and a rise in pediatric asthma diagnoses. Prominent trends expected during the forecast period involve personalized asthma treatment approaches, the use of telemedicine and remote patient monitoring, the continued development of biologic and targeted therapies, innovations in inhalation devices, and a heightened emphasis on pediatric asthma care.
Get A Free Sample Report With In-Depth Market Insights:
Asthma Drugs Market Growth Factors Behind Sustained Expansion
An increasing incidence of respiratory ailments is expected to propel the asthma drug market. These conditions impact the respiratory system, encompassing vital components such as the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. The widespread occurrence of respiratory illnesses necessitates the use of asthma medications to control and relieve symptoms linked to these conditions. With respiratory diseases becoming more common, especially conditions such as asthma that feature chronic inflammation and constricted airways, the need for efficacious treatments grows. For example, a research study published in December 2023 by JAMA Network Open, a medical journal from the American Medical Association, indicated that the global impact of chronic obstructive pulmonary disease (COPD) is projected to result in nearly 600 million cases worldwide by 2050, representing a 23% rise in its prevalence. Consequently, the growing prevalence of respiratory diseases is set to advance the asthma drug market.
Asthma Drugs Market Segment Outlook: Which Categories Are Growing Fastest?
The asthma drugs market covered in this report is segmented –
1) By Type Of Asthma: Allergic, Non-Allergic
2) By Asthma Trigger Type: Adult-Onset Asthma, Child-Onset Asthma, Cough-Induced Asthma, Exercise-Induced Asthma, Occupational Asthma, Nocturnal Asthma, Steroid-Resistant Asthma
3) By Therapy: Preventive
4) By Drug Class: Bronchodilators, Monoclonal Antibodies, Anti-Inflammatory Drugs, Combination Drugs
5) By End-User: Asthma Patients
Subsegments:
1) By Allergic: Inhaled Corticosteroids (ICS), Leukotriene Receptor Antagonists (LTRAs), Monoclonal Antibodies
2) By Non-Allergic: Short-Acting Beta Agonists (SABAs), Long-Acting Beta Agonists (LABAs), Oral Corticosteroids
Asthma Drugs Market Industry Trends Fueling Future Revenue Growth
Leading companies in the asthma drug market are prioritizing product innovation, such as fixed-dose triple-drug combinations, to enhance lung function, improve symptom management, and reduce severe asthma episodes in patients with uncontrolled conditions. These fixed-dose triple-drug combinations integrate multiple therapeutic agents into a single inhalation therapy, aiming to boost treatment adherence and overall efficacy. As an illustration, in January 2023, Lupin Ltd., an India-based pharmaceutical firm, introduced DIFIZMA, a fixed-dose combination comprising indacaterol, glycopyrronium, and mometasone, designed for treating inadequately controlled asthma in adults and adolescents aged twelve years and older. Endorsed by the Drug Controller General of India (DCGI), DIFIZMA broadened Lupin’s respiratory product line, being the sole fixed-dose triple-drug combination available for asthma patients seeking enhanced symptom control. Lupin specializes in the development and production of a diverse array of pharmaceutical goods, including inhalation treatments for various respiratory conditions.
Asthma Drugs Market Leading Companies And Competitive Benchmarking
Major companies operating in the asthma drugs market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC., GlaxoSmithKline PLC., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Novartis International AG, Mylan N.V., Cipla Limited, Chiesi Farmaceutici S.p.A., Sun Pharmaceutical Industries Limited, Hikma Pharmaceuticals, Mundipharma International Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Hetero Drugs Limited, Alembic Pharmaceuticals Limited, Sunovion Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc., Beximco Pharmaceuticals Ltd., Innoviva Inc., Vectura Group, Circassia Group PLC, Pulmatrix Inc.
View The Full Asthma Drugs Market Report:
Asthma Drugs Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the asthma drugs market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model